Repligen (NASDAQ:RGEN) Issues Earnings Results

Key Points

• Repligen reported $0.37 EPS for the quarter, which was $0.03 below analysts' expectations, and updated its FY 2025 guidance to 1.650-1.720 EPS.
• The company experienced a 14.8% increase in quarterly revenue year-over-year, although it recorded a negative net margin of 3.93%.
• Several analysts have given mixed ratings, with five providing hold ratings and nine issuing buy ratings, reflecting a current average rating of "Moderate Buy".

Repligen (NASDAQ:RGEN - Get Free Report) released its earnings results on Tuesday. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03), Briefing.com reports. The firm had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. Repligen had a positive return on equity of 4.65% and a negative net margin of 2.05%. The business's quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.40 EPS. Repligen updated its FY 2025 guidance to 1.650-1.720 EPS.

Repligen Stock Up 1.6%

Shares of NASDAQ RGEN traded up $1.84 during midday trading on Friday, reaching $118.91. 941,488 shares of the company's stock were exchanged, compared to its average volume of 783,381. Repligen has a 52-week low of $102.96 and a 52-week high of $182.52. The stock has a market capitalization of $6.68 billion, a PE ratio of -475.62, a price-to-earnings-growth ratio of 2.27 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. The business's fifty day moving average price is $123.39 and its two-hundred day moving average price is $136.49.

Institutional Trading of Repligen

Several hedge funds and other institutional investors have recently bought and sold shares of RGEN. Goldman Sachs Group Inc. grew its holdings in shares of Repligen by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company's stock valued at $18,067,000 after purchasing an additional 20,375 shares during the last quarter. Jones Financial Companies Lllp boosted its position in shares of Repligen by 3,850.6% during the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company's stock worth $814,000 after buying an additional 6,238 shares during the period. Finally, AQR Capital Management LLC acquired a new position in shares of Repligen during the first quarter worth approximately $262,000. 97.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

RGEN has been the topic of a number of recent research reports. Wells Fargo & Company lowered their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a report on Wednesday. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Barclays started coverage on Repligen in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price target for the company. Stephens upgraded Repligen to an "overweight" rating and set a $160.00 target price for the company in a research report on Tuesday, July 22nd. Finally, JPMorgan Chase & Co. dropped their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Repligen currently has a consensus rating of "Moderate Buy" and a consensus price target of $169.45.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.